Hagerman Allison 4

What Happened
Allison Hagerman, Chief Technology Officer of Oncolytics Biotech Inc. (ONCY), was granted a derivative award covering 260,000 shares on June 1, 2026. The Form 4 reports the acquisition price as $0.00 because this is an option-style grant; the exercise price is set equal to the closing price of ONCY common stock on the Nasdaq on the grant date, so the award had no intrinsic value at grant. The options vest in three equal annual installments, with the first tranche vesting June 1, 2027, subject to continued service.

Key Details

• Transaction date: 2026-06-01; filing date: 2026-06-03 (Form 4 accession 0001493152-26-027080).
• Transaction code: A (award/grant — derivative). Reported acquisition: 260,000 shares; reported price $0.00.
• Exercise price: equal to Nasdaq closing price on 2026-06-01 (per footnote). This implies no immediate intrinsic value at grant.
• Vesting: three equal annual installments; first vesting 2027-06-01, subject to continued employment.
• Shares owned after the transaction: not specified in the provided filing details.
• Filing timeliness: Form filed on 2026-06-03 (no late-filing flag reported).

Context
This was a standard retention/compensation option grant, not a purchase or sale—no shares were sold or bought in the open market. For retail investors, such grants signal executive compensation and future potential alignment with shareholder value but do not represent an immediate cash investment or divestiture.